GlassScriptPhysician profile
Kay L Conradt
NPI 1316989056
$4,126.59
in general payments reported to CMS, 2019-2025
32 companies · $917 in 2025
The $917 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $683 · 2022: $620 · 2023: $822 · 2024: $1,085 · 2025: $917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,802 · Education: $21.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,802.19 |
| Education | $21.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $837.81 | 2021-2025 | Tavneos, Krystexxa, Parsabiv |
| Novartis Pharmaceuticals Corporation | $403.69 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $268.47 | 2022-2025 | Tarpeyo |
| Ardelyx, INC. | $238.49 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Astrazeneca Pharmaceuticals LP | $207.85 | 2021-2024 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $186.79 | 2021-2023 | Rayaldee |
| Travere Therapeutics, INC. | $172.31 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $167.65 | 2021-2025 | Jynarque |
| Vifor Pharma, INC. | $153.18 | 2021-2023 | Korsuva, Veltassa |
| Fresenius USA Marketing, INC. | $145.68 | 2021-2025 | Velphoro, Velphoro |
| Glaxosmithkline, LLC. | $140.90 | 2021-2025 | Benlysta |
| Sanofi-Aventis U.S. LLC | $124.50 | 2025 | |
| Alexion Pharmaceuticals, INC. | $119.26 | 2021-2025 | Ultomiris |
| Akebia Therapeutics INC | $116.53 | 2021 | |
| Lilly USA, LLC | $92.08 | 2024-2025 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.52 | 2022-2024 | Gattex |
| Daiichi Sankyo INC. | $74.11 | 2021-2023 | Injectafer |
| Ultragenyx Pharmaceutical INC. | $65.40 | 2022-2024 | Crysvita |
| Ani Pharmaceuticals, INC. | $63.11 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $58.20 | 2024-2025 | Acthar |
| Horizon Therapeutics Plc | $57.72 | 2021-2023 | Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.93 | 2024-2025 | Jardiance |
| Novo Nordisk INC | $48.13 | 2023-2025 | Ozempic, Wegovy |
| Aurinia Pharma U.S., INC. | $43.30 | 2022-2025 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $36.97 | 2021-2023 | |
| Genzyme Corporation | $34.31 | 2021 | |
| Kyowa Kirin, INC. | $28.28 | 2023 | Crysvita |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.21 | 2023-2025 | |
| Lexicon Pharmaceuticals, INC. | $26.57 | 2024 | |
| Apellis Pharmaceuticals, INC. | $23.21 | 2025 | |
| Alnylam Pharmaceuticals INC. | $16.06 | 2024 | Onpattro |
| Chiesi USA, INC. | $14.37 | 2025 | Elfabrio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kay Conradt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.